Intelligence · Clinical Development
Pipeline search results
Programs matching “nivolumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 40 pipeline programs matching "nivolumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
NIVOLUMAB for Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
CERO THERAPEUTICS HOLDINGS, INC.
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer
1 trial -
Nivolumab
Shanghai Reinovax Biologics Co.,LTD
Metastatic Kidney Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Bladder Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Brain Neoplasms
1 trial -
Nivolumab
Ono Pharmaceutical Co.,
Gastric Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Colorectal Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Gastric Cancer
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Bladder Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Head and Neck Cancer
1 trial -
nivolumab
Bristol-Myers Squibb
Breast Cancer
1 trial -
CM-24 and Nivolumab - Dose Escalation
PURPLE BIOTECH LTD.
Solid Tumor
1 trial -
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Nektar Therapeutics UK Limited
Melanoma
1 trial -
IPILIMUMAB, NIVOLUMAB
Ningbo Cancer Hospital
type B3 thymoma and thymic carcinoma
1 trial -
NIVOLUMAB
Disc Medicine
Peritoneal Mesothelioma
1 trial -
NIVOLUMAB, BT5528
BICYCLE THERAPEUTICS
Advanced Malignancies Associated with EphA2 Expression
1 trial -
NIVOLUMAB, TEDOPI
Fondazione Telethon ETS
metastatic non-small-cell lung cancer
1 trial -
Nivolumab
Takeda
Relapsed Multiple Myeloma
1 trial -
Nivolumab
Bristol-Myers Squibb
Prostate Cancer
1 trial -
Nivolumab
United Therapeutics Europe Ltd
Metastatic Uveal Melanoma
1 trial -
Nivolumab
Bristol-Myers Squibb
Hepatocellular Carcinoma
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Ependymoma
1 trial -
Nivolumab
Adaptive Biotechnologies Corp
Bladder Cancer
1 trial -
Nivolumab
Atrium Therapeutics
Multiple Myeloma
1 trial -
Nivolumab
Mereo BioPharma Group plc
Ovarian Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.